BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset
SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision oncology diagnostics and therapeutics, today...
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
SAN FRANCISCO and SUZHOU, China, Jan. 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...